Kamada (NASDAQ:KMDA – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Kamada to related businesses based on the strength of its valuation, risk, earnings, institutional ownership, analyst recommendations, dividends and profitability.
Institutional and Insider Ownership
20.4% of Kamada shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Volatility & Risk
Kamada has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Kamada’s competitors have a beta of -1.84, suggesting that their average share price is 284% less volatile than the S&P 500.
Profitability
This table compares Kamada and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kamada | 12.67% | 9.36% | 6.53% |
| Kamada Competitors | -12,224.09% | -202.33% | -31.23% |
Dividends
Kamada pays an annual dividend of $0.13 per share and has a dividend yield of 1.6%. Kamada pays out 30.2% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 1.4% and pay out 48.3% of their earnings in the form of a dividend. Kamada is clearly a better dividend stock than its competitors, given its higher yield and lower payout ratio.
Earnings & Valuation
This table compares Kamada and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Kamada | $180.46 million | $20.20 million | 18.81 |
| Kamada Competitors | $727.19 million | $10.07 million | -18.81 |
Kamada’s competitors have higher revenue, but lower earnings than Kamada. Kamada is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Kamada and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kamada | 0 | 0 | 4 | 0 | 3.00 |
| Kamada Competitors | 9919 | 15313 | 45656 | 1602 | 2.54 |
Kamada presently has a consensus price target of $13.75, suggesting a potential upside of 69.96%. As a group, “Biotechnology” companies have a potential upside of 126.44%. Given Kamada’s competitors higher possible upside, analysts plainly believe Kamada has less favorable growth aspects than its competitors.
Summary
Kamada beats its competitors on 11 of the 15 factors compared.
About Kamada
Kamada Ltd. is an Israeli biopharmaceutical company that develops, manufactures and markets plasma-derived therapies and specialty pharmaceutical products. Founded in 1990, the company is headquartered in Rehovot, Israel. Its products include Glassia, an alpha-1 proteinase inhibitor used to treat people with alpha-1 antitrypsin deficiency, and immune globulin therapies for conditions including rabies exposure, cytomegalovirus infection and varicella-zoster exposure. Kamada serves markets in the United States and internationally, selling products directly and through commercial partners.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.
